Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects.


Journal

Journal of obesity
ISSN: 2090-0716
Titre abrégé: J Obes
Pays: United States
ID NLM: 101526295

Informations de publication

Date de publication:
2019
Historique:
received: 21 11 2018
revised: 13 12 2018
accepted: 19 12 2018
entrez: 14 3 2019
pubmed: 14 3 2019
medline: 11 8 2020
Statut: epublish

Résumé

This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in overweight to moderately obese adults. A double-blind, randomized, placebo-controlled trial involved one hundred and eight subjects (BMI between 25 and 35 kg/m After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the placebo (5.03 ± 2.50 kg vs. 0.98 ± 2.06 kg, respectively; These findings indicate that IQP-AE-103 could be an effective and safe weight loss intervention. This trial is registered with NCT03058367.

Identifiants

pubmed: 30863632
doi: 10.1155/2019/3412952
pmc: PMC6377993
doi:

Substances chimiques

Anti-Obesity Agents 0
Inulin 9005-80-5

Banques de données

ClinicalTrials.gov
['NCT03058367']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3412952

Commentaires et corrections

Type : ErratumIn

Références

Regul Toxicol Pharmacol. 1999 Dec;30(3):268-82
pubmed: 10620476
Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48
pubmed: 10702749
Arch Intern Med. 2000 Apr 10;160(7):898-904
pubmed: 10761953
Acta Psychol (Amst). 2000 Mar;104(1):1-15
pubmed: 10769936
Singapore Med J. 2001 Jan;42(1):6-10
pubmed: 11361230
Dig Liver Dis. 2002 Sep;34 Suppl 2:S12-8
pubmed: 12408433
J Am Diet Assoc. 2002 Nov;102(11):1621-30
pubmed: 12449285
Cochrane Database Syst Rev. 2004;(3):CD004094
pubmed: 15266516
J Nutr. 2004 Sep;134(9):2293-300
pubmed: 15333719
Drug Saf. 2006;29(4):277-302
pubmed: 16569079
Ann Pharmacother. 2006 Oct;40(10):1717-23
pubmed: 16940406
Obes Rev. 2008 Mar;9(2):104-7
pubmed: 17986177
BMJ. 2007 Dec 8;335(7631):1194-9
pubmed: 18006966
J Occup Environ Med. 2008 Jan;50(1):39-45
pubmed: 18188080
J Occup Environ Med. 2007 Dec;49(12):1317-24
pubmed: 18231079
Public Health Nutr. 2009 Feb;12(2):222-7
pubmed: 18662489
Bull World Health Organ. 2008 Aug;86(8):577
pubmed: 18797606
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
Diabetes Care. 2010 Aug;33(8):1850-2
pubmed: 20484131
Obes Res Clin Pract. 2010 Jul;4(3):e171-e181
pubmed: 21116472
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
J Health Econ. 2012 Jan;31(1):219-30
pubmed: 22094013
Obesity (Silver Spring). 2013 Jan;21(1):58-64
pubmed: 23505169
Dig Dis Sci. 2013 Aug;58(8):2177-86
pubmed: 23606109
Phytother Res. 2014 Feb;28(2):268-73
pubmed: 23606408
Obesity (Silver Spring). 2014 Mar;22(3):645-51
pubmed: 24006357
Diabetes. 2013 Oct;62(10):3341-9
pubmed: 24065795
Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38
pubmed: 24222017
Carbohydr Polym. 2014 Jan 30;101:368-78
pubmed: 24299785
Curr Ther Res Clin Exp. 2004 Mar;65(2):127-37
pubmed: 24936112
Curr Ther Res Clin Exp. 2014 Jun 21;76:39-44
pubmed: 25067985
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Food Funct. 2015 Dec;6(12):3728-36
pubmed: 26359588
J Obes. 2015;2015:953138
pubmed: 26435849
Nutr Metab (Lond). 2015 Oct 24;12:36
pubmed: 26500686
Rev Paul Pediatr. 2016 Jan-Mar;34(1):47-55
pubmed: 26830602
Cell Metab. 2016 Apr 12;23(4):591-601
pubmed: 26916363
Carbohydr Polym. 2016 Aug 20;147:444-454
pubmed: 27178951
J Gerontol A Biol Sci Med Sci. 2017 Dec 12;73(1):73-80
pubmed: 28003374
Aust Fam Physician. 2017;46(7):460-463
pubmed: 28697288
Nahrung. 1987;31(5-6):427-36
pubmed: 3657917
Obes Res. 1995 Sep;3 Suppl 2:211s-216s
pubmed: 8581779
Am J Clin Nutr. 1997 May;65(5):1397-402
pubmed: 9129468

Auteurs

Ralf Uebelhack (R)

analyze & realize GmbH, Weißenseer Weg 111, 10369 Berlin, Germany.

Udo Bongartz (U)

analyze & realize GmbH, Weißenseer Weg 111, 10369 Berlin, Germany.

Stephanie Seibt (S)

analyze & realize GmbH, Waldseeweg 6, 13467 Berlin, Germany.

Gordana Bothe (G)

analyze & realize GmbH, Waldseeweg 6, 13467 Berlin, Germany.

Pee Win Chong (PW)

Zaluvida Corporate Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, Malaysia.

Patricia De Costa (P)

InQpharm Group Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, Malaysia.

Natalia Wszelaki (N)

Zaluvida Corporate Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH